Anticancer agent 135 is a potent androgen receptor (AR) antagonist that effectively blocks AR nuclear translocation and inhibits AR/AR-V7 heterodimerization, thereby suppressing downstream gene transcription; it demonstrates potent efficacy in prostate cancer xenograft models.